Latest Insider Transactions at Y M Abs Therapeutics, Inc. (YMAB)
This section provides a real-time view of insider transactions for Y M Abs Therapeutics, Inc. (YMAB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Y-mAbs Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Y-mAbs Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 19
2024
|
Thomas Gad CHIEF BUSINESS OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
22,831
+11.17%
|
$91,324
$4.38 P/Share
|
|
Sep 16
2024
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
30,000
-30.71%
|
$360,000
$12.97 P/Share
|
|
Sep 13
2024
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
65,000
-39.96%
|
$845,000
$13.47 P/Share
|
|
Aug 28
2024
|
Torben Lund Hansen SVP & CHIEF TECHNICAL OFFICER |
SELL
Open market or private sale
|
Direct |
50,000
-58.41%
|
$750,000
$15.37 P/Share
|
|
Aug 28
2024
|
Torben Lund Hansen SVP & CHIEF TECHNICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+36.87%
|
$200,000
$4.38 P/Share
|
|
Aug 26
2024
|
Joris Wilms SVP & CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
5,000
-14.04%
|
$70,000
$14.69 P/Share
|
|
Jul 12
2024
|
Peter P. Pfreundschuh CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
46,000
+50.0%
|
-
|
|
Jun 11
2024
|
Ashu Tyagi Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,495
+37.5%
|
-
|
|
Jun 11
2024
|
David N Gill Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,495
+37.5%
|
-
|
|
Jun 11
2024
|
James Healy Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,495
+9.96%
|
-
|
|
Jun 11
2024
|
Johan Wedell Wedellsborg Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,495
+37.5%
|
-
|
|
Jun 11
2024
|
Laura Hamill Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,495
+37.5%
|
-
|
|
Jun 11
2024
|
Mary Tagliaferri Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,495
+30.0%
|
-
|
|
Jun 11
2024
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
35,000
-17.71%
|
$420,000
$12.0 P/Share
|
|
Jun 10
2024
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
35,000
-15.04%
|
$420,000
$12.03 P/Share
|
|
Jun 10
2024
|
Gerard Ber Director |
SELL
Open market or private sale
|
Direct |
722
-30.99%
|
$8,664
$12.0 P/Share
|
|
May 31
2024
|
Bo Kruse EVP, CFO, SECRY & TREAS. |
SELL
Open market or private sale
|
Direct |
31,371
-12.95%
|
$376,452
$12.07 P/Share
|
|
May 31
2024
|
Bo Kruse EVP, CFO, SECRY & TREAS. |
BUY
Exercise of conversion of derivative security
|
Direct |
31,371
+11.47%
|
$62,742
$2.0 P/Share
|
|
May 30
2024
|
Bo Kruse EVP, CFO, SECRY & TREAS. |
SELL
Open market or private sale
|
Direct |
28,629
-11.95%
|
$343,548
$12.03 P/Share
|
|
May 30
2024
|
Bo Kruse EVP, CFO, SECRY & TREAS. |
BUY
Exercise of conversion of derivative security
|
Direct |
28,629
+10.68%
|
$57,258
$2.0 P/Share
|
|
May 23
2024
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
7,351
-3.06%
|
$95,563
$13.0 P/Share
|
|
May 21
2024
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
25,000
-9.43%
|
$300,000
$12.0 P/Share
|
|
Mar 12
2024
|
Mary Tagliaferri Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,660
+50.0%
|
-
|
|
Mar 05
2024
|
Susan Laura Smith SVP & CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,682
-4.72%
|
$26,912
$16.55 P/Share
|
|
Mar 05
2024
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
3,900
-2.4%
|
$62,400
$16.44 P/Share
|
|
Mar 05
2024
|
Vignesh Rajah SVP & CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,711
-4.81%
|
$27,376
$16.53 P/Share
|
|
Feb 12
2024
|
Michael J Rossi PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
35,700
+50.0%
|
-
|
|
Jan 18
2024
|
Susan Laura Smith SVP & CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
17,800
+33.33%
|
-
|
|
Jan 18
2024
|
Vignesh Rajah SVP & CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
17,800
+33.33%
|
-
|
|
Jan 18
2024
|
Joris Wilms SVP & CHIEF OPERATING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
17,800
+33.33%
|
-
|
|
Jan 18
2024
|
Steen Lisby SVP & CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
17,800
+33.33%
|
-
|
|
Jan 18
2024
|
Thomas Gad CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
22,100
+11.97%
|
-
|
|
Jan 18
2024
|
Torben Lund Hansen SVP & CHIEF TECHNICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
17,800
+33.33%
|
-
|
|
Jan 18
2024
|
Bo Kruse EVP, CFO, SECRY & TREAS. |
BUY
Grant, award, or other acquisition
|
Direct |
18,100
+7.9%
|
-
|
|
Dec 21
2023
|
Thomas Gad CHIEF BUSINESS OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+26.25%
|
$100,000
$2.0 P/Share
|
|
Dec 15
2023
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
50,000
-15.87%
|
$300,000
$6.61 P/Share
|
|
Dec 14
2023
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
50,000
-13.7%
|
$300,000
$6.83 P/Share
|
|
Dec 13
2023
|
Thomas Gad CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect |
50,000
-12.05%
|
$300,000
$6.58 P/Share
|
|
Dec 11
2023
|
Johan Wedell Wedellsborg Director |
BUY
Open market or private purchase
|
Indirect |
109,318
+1.18%
|
$655,908
$6.93 P/Share
|
|
Dec 11
2023
|
Biotech Ap S Wg Director |
BUY
Open market or private purchase
|
Direct |
109,318
+1.18%
|
$655,908
$6.93 P/Share
|
|
Dec 08
2023
|
Johan Wedell Wedellsborg Director |
BUY
Open market or private purchase
|
Indirect |
18,503
+0.41%
|
$111,018
$6.99 P/Share
|
|
Dec 08
2023
|
Biotech Ap S Wg Director |
BUY
Open market or private purchase
|
Direct |
18,503
+0.41%
|
$111,018
$6.99 P/Share
|
|
Dec 07
2023
|
Johan Wedell Wedellsborg Director |
BUY
Open market or private purchase
|
Indirect |
6,183
+0.14%
|
$37,098
$6.5 P/Share
|
|
Dec 07
2023
|
Biotech Ap S Wg Director |
BUY
Open market or private purchase
|
Direct |
6,183
+0.14%
|
$37,098
$6.5 P/Share
|
|
Nov 29
2023
|
Johan Wedell Wedellsborg Director |
BUY
Open market or private purchase
|
Indirect |
51,837
+1.16%
|
$259,185
$5.97 P/Share
|
|
Nov 29
2023
|
Biotech Ap S Wg Director |
BUY
Open market or private purchase
|
Direct |
51,837
+1.16%
|
$259,185
$5.97 P/Share
|
|
Nov 28
2023
|
Biotech Ap S Wg Director |
BUY
Open market or private purchase
|
Direct |
30,671
+0.7%
|
$153,355
$5.81 P/Share
|
|
Nov 28
2023
|
Johan Wedell Wedellsborg Director |
BUY
Open market or private purchase
|
Indirect |
30,671
+0.7%
|
$153,355
$5.81 P/Share
|
|
Nov 27
2023
|
Biotech Ap S Wg Director |
BUY
Open market or private purchase
|
Direct |
62,516
+1.42%
|
$312,580
$5.49 P/Share
|
|
Nov 27
2023
|
Johan Wedell Wedellsborg Director |
BUY
Open market or private purchase
|
Indirect |
62,516
+1.42%
|
$312,580
$5.49 P/Share
|